Larry Tiffany is Chairman of the Board of gel-e. Larry is a serial entrepreneur having most recently founded and led to the sale of the neuro-molecular testing company DioGenix. While at the helm of DioGenix, Larry raised over $12M from early stage investors while garnering another $2M in non-dilutive sources (e.g. the National MS Society) to support the clinical development and prospective validation of the first new diagnostic for Multiple Sclerosis since the late 50’s, MSPrecise®. Prior to DioGenix, Larry held positions in Sr. Management at Ore Pharmaceuticals (CBO), Gene Logic (SVP & GM, Genomics) and Genetraks (US President). He holds a JD from Franklin Pierce Law Center in Concord, New Hampshire (specializing in intellectual and commercial law); a MS in Biotechnology from Johns Hopkins University in Baltimore, Maryland; and a BS in Biochemistry from Nazareth College in Rochester, New York.
Matthew Dowling, Ph.D. is Founder and Chief Scientific Officer of gel-e. Matt completed his graduate work at the Fischell Department of Bioengineering at the University of Maryland in May 2010 and has since pursued gel-e on a full-time basis. In 2005, after graduating in chemical engineering from the University of Notre Dame, he was awarded the Fischell Fellowship in Biomedical Engineering for his innovative ideas in drug delivery systems. Matt then co-created the gel-e platform, raising $165,000 in initial grants to develop the technology, which led to being named the Dean’s Doctoral Research Award from the UMD Clark School of Engineering for his work on chitosan-based self-assembled soft materials for use in wound treatment. He has since successfully licensed gel-e from UMD and has raised another $2.0M in non-dilutive funding which has been astutely used to achieve a first FDA clearance for gel-e, a large and growing patent estate and numerous peer-reviewed publications in high-impact journals.
Rich Vincent is the Chief Financial Officer of gel-e. Rich previously held senior management positions at Meritage Pharma, Sorrento Therapeutics, Elevation Pharmaceuticals, Verus Pharmaceuticals, Women First HealthCare, Elan Pharmaceuticals, Phase Metrics, and Deloitte & Touche LLP, where he specialized in emerging growth and publicly-traded companies. Over the past 20+ years, Rich’s experience includes raising over $550 million through venture capital, major commercial banks and institutions, public offering proceeds for high growth pharmaceutical and technology-based companies, and participating in a number of acquisitions and divestitures valued at over $1 billion. Rich was named 2014 public company CFO of the Year in San Diego by the San Diego Business Journal.
Elsa Abruzzo is the Head of Regulatory at gel-e. Over 29+ years, Elsa has helped numerous disruptive technologies reach successful commercialization with US and International regulatory approvals, including: implantable biomaterials, transcatheter heart valves (TAVR), stents, atrial fibrillation ablation devices, orthopedic navigation systems, drug delivery devices, point of care analyzers, and wearable technologies. As President of Cygnus Regulatory since 2008, Elsa specializes in regulatory and clinical strategy, quality assurance, due diligence, and project management. Ms. Abruzzo is regulatory affairs certified (RAC) and a Regulatory Affairs Professional Society (RAPS) Fellow (2010). An engineer by training, Ms. Abruzzo has worked in leadership roles at companies such as Baxter, Cordis JNJ, CryoLife, Percutaneous Valve Technologies (acquired by Edwards LifeSciences), AtriCure, InnerPulse, Merlin MD, Sapheon (acquired by Covidien), and PTS Diagnostics.
Alexander K. Arrow, MD, CFA is an Independent Director at gel-e. Alex is currently also the CEO of Zelegent, Inc., a medical technology company developing a minimally-invasive tool for otolaryngologist sleep specialists to treat snoring in a simple office-based procedure, and serves as the part-time CFO of Protagenic Therapeutics, Inc., an early-stage biotechnology company developing a novel neuro-active peptide drug. He previously served on the Board of Neumedicines, Inc., an immuno-oncology company developing a first-in-class broad-spectrum anti-cancer agent, and was a Director as well as President and Chief Operating Officer of Biolase, Inc. (NASDAQ: BIOL), the world’s lead manufacturer of dental lasers, where he also served as Chair of the Audit and Compensation committees of the Board of Directors. Prior to Biolase, Dr. Arrow was the Chief Medical Officer of Stanford-affiliated neuroscience company Circuit Therapeutics, Inc., and prior to that he spent five years as the Chief Financial Officer of cardiovascular device manufacturer Arstasis, Inc. As CFO of Arstasis, he was part of a team that raised over $100 million in five rounds and launched a first-in-class cardiovascular technology for interventional cardiologists.
Bruce Choi is a medical device professional with over 19 years of global experience in Quality, Research and Development, Operations, and Supply Chain at large multi-national and privately held start-up companies. Bruce is the Founder & CEO of Integral, a company that focuses on building Quality and Operational infrastructure for new medical device ventures. Previously, Bruce was the Director of Medtronic’s endoVenous Global Operations where he was responsible for the end-to-end values stream of products accounting for over $400 million in revenue. Bruce has a B.S. degree in Material Science & Engineering from Cornell University and a M.S. degree in Biomedical Engineering from Cal Poly.
David King, MD, LTC
Mayur Narayan, MD, MBA
U of Texas Southwestern
Joel Buzy, MD, FACEP
Shady Grove Adventist ER
Srinivasa Raghavan, PhD
University of Maryland
John Hess, MD
University of Washington